Business Context and Reporting Period
The provided filing is a Form 10-K for Zeta Acquisition Corp. II, not Whitehawk Therapeutics, Inc., for the fiscal year ended December 31, 2016. Zeta was a Delaware blank-check and shell company formed to pursue a merger or acquisition and had no operating business, employees, revenue, or material assets other than cash.
As of December 31, 2016, Zeta was in late-stage negotiations for a proposed business combination with Aerpio Therapeutics, Inc.; no definitive agreement had been entered into and closing was not assured. The filing was signed March 7, 2017.
Financial Metrics
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Net loss | $(39,434) | $(31,440) |
| General and administrative expense | $29,492 | $23,006 |
| Interest expense | $9,942 | $8,434 |
| Cash used in operating activities | $(24,517) | $(21,734) |
| Cash provided by financing activities | $10,000 | $35,000 |
| Year-end cash and cash equivalents | $4,012 | $18,529 |
| Total liabilities | $229,927 | $205,010 |
| Stockholders' deficit | $(225,915) | $(186,481) |
Loss per basic and diluted share was $0.01 in both periods, based on 5,000,000 weighted-average shares. The company had no meaningful revenue or operating margin; it generated no cash flow from operations and had no debt other than notes payable to stockholders and related accrued interest.
At December 31, 2016, stockholder notes payable totaled $170,000, were unsecured, bore interest at 6%, and were due on demand. Accrued and unpaid interest totaled $42,378. The company reported no off-balance-sheet arrangements and paid no dividends.
Material Changes Versus the Prior Comparable Period
- Net loss increased by $7,994, or approximately 25%, primarily due to higher general and administrative and interest expense.
- Cash declined by $14,517, from $18,529 to $4,012, as operating cash use exceeded $10,000 of stockholder financing.
- Total liabilities increased by $24,917, including a $10,000 increase in stockholder notes payable and higher accrued interest and expenses.
- Stockholders’ deficit increased from $(186,481) to $(225,915), reflecting the 2016 net loss.
- Management had not completed a business combination and continued to rely on related-party financing and potential future equity financing.
Guidance, Outlook, Risks, and Unusual Items
Management’s objective was to locate and complete a single business combination rather than generate near-term earnings. The proposed Aerpio transaction contemplated exchanging Aerpio shares for 18,000,000 shares of Zeta common stock, while existing Zeta holders would sell 1,000,000 shares and cancel 4,000,000 shares. The transaction could materially change ownership and dilute existing holders, but the filing states that completion was uncertain.
Management disclosed substantial doubt regarding the company’s ability to continue as a going concern. It expected to fund reporting, acquisition-investigation, and transaction costs through its limited cash, deferred service-provider fees, related-party advances, and additional financing. There was no assurance that additional funding would be available or that a suitable transaction would be completed.
- The company was a shell and blank-check entity with nominal assets, no revenues, and no operating history.
- Cash of $4,012 was substantially below current liabilities of $229,927.
- Stockholder loans were due on demand, creating liquidity and related-party financing risk.
- Management had limited time and resources for due diligence and acknowledged that a target could be financially unstable or in an early development stage.
- Competition for acquisition targets could come from better-capitalized public shells, blank-check companies, and strategic buyers.
- The company was not listed on a public market, had four holders of record as of March 7, 2017, and management and affiliated holders controlled approximately 80% of the outstanding shares.
- The independent auditor issued an unqualified opinion on the financial statements but did not attest to internal control effectiveness because the company qualified for applicable smaller-reporting-company exemptions.
- A full valuation allowance was recorded against deferred tax assets, and the company reported an estimated net operating loss carryforward of approximately $42,400.
Important Facts to Verify
- Verify the issuer identity: the supplied filing names Zeta Acquisition Corp. II, while the request metadata identifies Whitehawk Therapeutics, Inc.
- Verify whether the proposed Aerpio merger was subsequently executed, terminated, or materially amended.
- Verify the company’s post-2016 name, ownership structure, capitalization, and share dilution following any business combination.
- Review subsequent filings for financing, repayment or restructuring of the $170,000 stockholder notes and accrued interest.
- Confirm the company’s ability to continue as a going concern given $4,012 of cash, negative working capital, no revenue, and dependence on related-party funding.